CN110638946A - Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura - Google Patents
Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura Download PDFInfo
- Publication number
- CN110638946A CN110638946A CN201910925553.0A CN201910925553A CN110638946A CN 110638946 A CN110638946 A CN 110638946A CN 201910925553 A CN201910925553 A CN 201910925553A CN 110638946 A CN110638946 A CN 110638946A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- alkaloid
- raw materials
- thrombocytopenic purpura
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 241000411851 herbal medicine Species 0.000 title claims abstract description 44
- 206010043561 Thrombocytopenic purpura Diseases 0.000 title claims abstract description 34
- 229930013930 alkaloid Natural products 0.000 claims abstract description 53
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 53
- 239000002994 raw material Substances 0.000 claims abstract description 36
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 35
- 229930003944 flavone Natural products 0.000 claims abstract description 35
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 35
- 235000011949 flavones Nutrition 0.000 claims abstract description 35
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 244000236655 Diospyros kaki Species 0.000 claims abstract description 28
- 235000011511 Diospyros Nutrition 0.000 claims abstract description 27
- 241001071917 Lithospermum Species 0.000 claims abstract description 27
- 241000123069 Ocyurus chrysurus Species 0.000 claims abstract description 27
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 26
- 239000000341 volatile oil Substances 0.000 claims abstract description 26
- 241000207925 Leonurus Species 0.000 claims abstract description 25
- 240000004274 Sarcandra glabra Species 0.000 claims abstract description 25
- 241000612166 Lysimachia Species 0.000 claims abstract description 23
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 23
- 241000203383 Schefflera Species 0.000 claims abstract description 22
- 241001537328 Corydalis decumbens Species 0.000 claims abstract description 10
- WTDHMFBJQJSTMH-UHFFFAOYSA-N hinokiflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C(OC=3C=CC(=CC=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)=C(O)C=C2O1 WTDHMFBJQJSTMH-UHFFFAOYSA-N 0.000 claims abstract description 8
- HLFVFEBKCLAGBY-UHFFFAOYSA-N hinokiflavone Natural products Oc1ccc(cc1)C2=COc3cc(O)c(Oc4ccc(cc4)C5=CC(=O)c6c(O)cc(O)cc6O5)c(O)c3C2=O HLFVFEBKCLAGBY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 240000007171 Imperata cylindrica Species 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 241000209020 Cornus Species 0.000 claims description 28
- 241000218176 Corydalis Species 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 240000002924 Platycladus orientalis Species 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 6
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 240000008027 Akebia quinata Species 0.000 claims description 4
- 235000007756 Akebia quinata Nutrition 0.000 claims description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 241000759833 Cornus officinalis Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- 241001278836 Agrimonia pilosa Species 0.000 claims description 2
- 235000000641 Agrimonia pilosa Nutrition 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 229930007845 β-thujaplicin Natural products 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 238000000944 Soxhlet extraction Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 23
- 210000005259 peripheral blood Anatomy 0.000 abstract description 8
- 239000011886 peripheral blood Substances 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 2
- 240000006766 Cornus mas Species 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 25
- 239000003814 drug Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- UFJORDZSBNSRQT-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-3-yl)-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C(C3=CC=CC=C3OC=2C=2C=CC=CC=2)=O)=C1C1=CC=CC=C1 UFJORDZSBNSRQT-UHFFFAOYSA-N 0.000 description 5
- 241001598107 Imperata Species 0.000 description 5
- 241000604017 Lysimachia sikokiana Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000016993 Agrimonia Nutrition 0.000 description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 235000008597 Diospyros kaki Nutrition 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 241001571764 Lysimachia christinae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 241000967218 Selaginella tamariscina Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241001530209 Swertia Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000234281 Tamarix gallica Species 0.000 description 1
- 235000014265 Tamarix gallica Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000004346 regulation of heart rate Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/44—Ebenaceae (Ebony family), e.g. persimmon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which is prepared from the following raw materials in parts by weight: 4-20 parts of dogwood extract, 2-15 parts of lysimachia, 8-20 parts of scandent schefflera root extract, 8-40 parts of glabrous sarcandra herb volatile oil extract, 8-35 parts of lithospermum extract, 12-60 parts of cogongrass rhizome, 35-70 parts of madder extract, 10-55 parts of corydalis decumbens alkaloid extract, 2-30 parts of persimmon leaf extract, 2-27 parts of hinokiflavone extract, 2-15 parts of hairyvein agrimony flavone extract and 2-25 parts of leonurus alkaloid extract. The Chinese herbal medicine composition has the obvious function of increasing the number of platelets in peripheral blood, can be used for preventing and treating thrombocytopenic purpura, and enables the number of platelets to reach a normal level, and the preparation method is used for detection, and is low in cost.
Description
Technical Field
The invention relates to the technical field of Chinese herbal medicines for preventing and treating thrombocytopenic purpura, in particular to a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura.
Background
Thrombocytopenic purpura is a hemorrhagic disease in which the skin and organs have a bleeding tendency and platelets are significantly reduced. And is classified into idiopathic or idiopathic thrombocytopenic purpura and secondary or symptomatic thrombocytopenic purpura. Clinically, the number of platelets is lower than the normal range of 14-40 ten thousand per mu l, hemorrhagic anemia is easy to cause if the platelets are not treated in time, intracranial hemorrhage and hemorrhagic shock can also occur seriously, and even the life is threatened.
At present, western medicines for treating thrombocytopenic purpura do not have specific medicines, individual treatment is needed according to different symptoms, glucocorticoid treatment is generally adopted, but after hormone is reduced or stopped, platelets are reduced, and large side effects such as central obesity, hypertension, diabetes and the like can be generated on a human body after the hormones are frequently used. The severe patients can use the gamma globulin with large dose, and other treatment methods such as splenectomy, plasmapheresis and the like can achieve certain curative effect, but the consumption is fast, the treatment cost is higher, the side effect is large, and once the medicine is stopped, the recurrence rate is higher.
Disclosure of Invention
In order to solve the technical problems, the invention aims to provide a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which has the obvious effect of increasing the number of platelets in peripheral blood, can be used for preventing and treating thrombocytopenic purpura to enable the number of platelets to reach a normal level, and has the advantages of low cost due to detection of a preparation method.
In order to achieve the above object, the technical solution of the present invention is as follows.
A Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura is prepared from the following raw materials in parts by weight: 4-20 parts of dogwood extract, 2-15 parts of lysimachia, 8-20 parts of scandent schefflera root extract, 8-40 parts of glabrous sarcandra herb volatile oil extract, 8-35 parts of lithospermum extract, 12-60 parts of cogongrass rhizome, 35-70 parts of madder extract, 10-55 parts of corydalis decumbens alkaloid extract, 2-30 parts of persimmon leaf extract, 2-27 parts of hinokiflavone extract, 2-15 parts of hairyvein agrimony flavone extract and 2-25 parts of leonurus alkaloid extract;
the dogwood extract, the lithospermum extract, the persimmon leaf extract, the Jiangnan Chinese arborvitae twig and leaf extract, the hairyvein agrimony flavone extract and the fiveleaf gynostemma herb extract are obtained by performing Soxhlet reflux extraction on ethanol and then concentrating; the lysimachia extract and the madder extract are obtained by ethanol extraction; the glabrous sarcandra herb volatile oil extract is obtained by steam distillation in water; the corydalis amabilis alkaloid extract and the leonurus alkaloid extract are obtained by ethanol hot extraction and acid-alkali precipitation.
Preferably, the feed additive is prepared from the following raw materials in parts by weight: 8-12 parts of dogwood extract, 2-8 parts of lysimachia extract, 8-12 parts of scandent schefflera root extract, 8-12 parts of glabrous sarcandra herb volatile oil extract, 8-12 parts of lithospermum extract, 25-40 parts of cogongrass rhizome, 50-55 parts of madder extract, 15-25 parts of corydalis decumbens alkaloid extract, 2-8 parts of persimmon leaf extract, 2-8 parts of Jiangnan Chinese arborvitae flavone extract, 2-8 parts of hairyvein agrimony flavone extract and 2-7 parts of leonurus alkaloid extract.
Preferably, the feed additive is prepared from the following raw materials in parts by weight: 10 parts of dogwood extract, 5 parts of lysimachia extract, 10 parts of scandent schefflera root extract, 10 parts of glabrous sarcandra herb volatile oil extract, 10 parts of lithospermum extract, 30 parts of rhizoma imperatae, 50 parts of madder extract, 20 parts of corydalis decumbens alkaloid extract, 10 parts of persimmon tree leaf extract, 10 parts of hinokiflavone extract, 10 parts of hairyvein agrimony flavone extract and 6 parts of leonurus alkaloid extract.
Preferably, the dogwood extract, the lithospermum extract, the persimmon leaf extract, the Jiangnan Chinese tamarisk biflavone extract, the hairyvein agrimony flavone extract and the scandent schefflera root extract are obtained by crushing raw materials, adding ethanol with the weight 10 times of that of the raw materials, performing Soxhlet reflux extraction at 70 ℃ in a water bath for 2 hours, and distilling an extracting solution under reduced pressure.
Preferably, the lysimachia extract is obtained by crushing the raw materials, adding ethyl acetate/ethanol mixed solution with the volume ratio of 1:1 which is 3 times the weight of the raw materials, extracting for 24 hours at normal temperature and normal pressure, decoloring the extracting solution by powdery active carbon with the weight of 3 percent of the raw materials, filtering, and distilling under reduced pressure.
Preferably, the madder root extract is obtained by crushing the raw materials, adding 25% ethanol which is 3 times of the weight of the raw materials, leaching at the temperature of 80 ℃, extracting for 2 hours, decoloring an extracting solution by using powdered activated carbon which is 3% of the weight of the raw materials, filtering, and distilling under reduced pressure.
Preferably, the glabrous sarcandra herb volatile oil extract is obtained by adding deionized water in an amount which is 5 times the weight of the raw materials after the raw materials are crushed, heating and distilling at 90 ℃ after wetting for 10min, collecting distillate, and slowly adding the distillate into an inclusion agent solution.
Preferably, the corydalis amabilis alkaloid extract and the leonurus alkaloid extract are obtained by crushing raw materials, adding 10 times of ethanol by weight of the raw materials, heating and extracting at 80 ℃ for 2 hours, concentrating an extracting solution to remove the ethanol, adding 5% hydrochloric acid to adjust the pH value to 2, standing for 10 hours, filtering, adding 15% sodium hydroxide to adjust the pH value to 12, and filtering.
The preparation method of the Chinese herbal medicine composition comprises the following steps:
s1, weighing 4-20 parts of dogwood extract, 2-15 parts of lysimachia extract, 8-20 parts of scandent schefflera root extract, 8-40 parts of glabrous sarcandra herb volatile oil extract, 8-35 parts of lithospermum extract, 12-60 parts of cogongrass rhizome, 35-70 parts of madder extract, 10-55 parts of corydalis decumbens alkaloid extract, 2-30 parts of persimmon leaf extract, 2-27 parts of hinokiflavone extract, 2-15 parts of hairyvein agrimony flavone extract and 2-25 parts of motherwort alkaloid extract;
s2, respectively crushing the dogwood extract, the lysimachia extract, the scandent schefflera root extract, the glabrous swertia herb volatile oil extract, the lithospermum extract, the madder extract, the corydalis amabilis alkaloid extract, the persimmon leaf extract, the Jiangnan Chinese arborvitae flavone extract, the hairyvein agrimonia herb flavone extract and the motherwort alkaloid extract which are weighed in the S1 to 80 meshes, and then mixing and stirring uniformly to obtain a mixture A;
s3, adding water in an amount which is 3 times the weight of the raw materials into the rhizoma imperatae weighed in S1, decocting for 3 times, wherein the decocting time is 30min each time, combining decoction, filtering, concentrating the filtrate into paste, drying and crushing to obtain an extract B;
s4, mixing the mixture A obtained in the step S2 and the extract B obtained in the step S3, and uniformly stirring to obtain the Chinese herbal medicine composition.
Preferably, the decoction temperature in S3 is 90 ℃.
Cornus officinalis has the effects of inhibiting platelet aggregation and resisting thrombosis, enhancing myocardial contractility, expanding peripheral blood vessels, enhancing heart pumping function and increasing blood pressure.
Laizi herb is also called common sage herb, and the whole herb is used as the medicine and has the efficacies of clearing away heat and toxic material, cooling blood and removing blood stasis, and inducing diuresis to alleviate edema.
Gynostemma pentaphylla, also called gynostemma pentaphylla, is used as a medicine by the whole herb and has seven bidirectional regulation functions: too high and too low blood pressure; the human body is too obese and too thin; regulation of heart rate, bradycardia, tachycardia; lipid metabolism; too many and too few real red blood cells; excessive and too little platelets and leukocytes; the regulation of the immune system etc. will automatically stabilize when regulated to normal.
The glabrous sarcandra herb has the effects of resisting bacteria and diminishing inflammation, dispelling wind and dredging collaterals, and promoting blood circulation to remove stasis.
Radix Arnebiae has effects of cooling blood, promoting blood circulation, clearing away heat and toxic materials.
The rhizoma imperatae is used as a medicine by taking rhizome, and has the effects of cooling blood and activating blood.
Madder has the effects of cooling blood, stopping bleeding, promoting blood circulation and removing blood stasis, can exert the coagulation promoting effect to stop bleeding, and has strong selective inhibition effect on platelet aggregation.
Rhizoma corydalis Decumbentis has effects of dispelling pathogenic wind, removing dampness, relieving rigidity of muscles, promoting blood circulation, dredging collaterals, relieving pain, and lowering blood pressure.
Persimmon leaves have the functions of reducing blood fat, promoting urination, relaxing bowels, relieving swelling, softening blood vessels, enhancing elasticity of blood vessels and improving the immune function of organisms.
Herba Selaginellae Involventis has effects of clearing heat, promoting diuresis, promoting blood circulation and relieving swelling.
The whole herb of hairyvein agrimony, also called as western agrimony, is a strong astringent hemostatic with the effects of strengthening heart, raising blood pressure, blood coagulation, hemostasis, cooling blood, antibiosis and the like, and is widely used for various bleeding diseases.
Herba Leonuri has effects of promoting blood circulation, dispelling blood stasis, regulating menstruation, inducing diuresis, relieving swelling, and contracting uterus.
Compared with the prior art, the invention has the following beneficial effects:
1. the Chinese herbal medicine composition provided by the invention mainly takes cornus officinalis and madder which have the effects of inhibiting platelet aggregation and resisting thrombosis as monarch drugs, lysimachia, lithospermum, imperata rhizome, selaginella tamariscina and agrimonia pilosa which have the effects of clearing heat, cooling blood, promoting blood circulation and detoxifying as ministerial drugs, and takes fiveleaf gynostemma herb, lithospermum, rhizoma imperatae, corydalis decumbentis, persimmon leaves and motherwort as adjuvant drugs, so that the Chinese herbal medicine composition has the effects of promoting blood circulation, dredging collaterals and inducing diuresis, can improve the immune function of an organism, plays a role in bidirectional regulation, enables the regulation of an immune system and the like to be regulated to a normal level, and is automatically stabilized. The traditional Chinese medicine composition provided by the invention has the effects of stopping bleeding, cooling blood and activating blood circulation, is penetrated through the treatment process, has the mutual coordination effect, can obviously increase the number of platelets in peripheral blood, can reach the normal level, has the obvious effect rate of more than 85%, and also has the effect of recovering the functions of liver and kidney.
2. The Chinese herbal medicine composition disclosed by the invention is small in dosage, free of toxic and side effects, capable of enhancing the immune function of a patient and convenient to take orally.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without any inventive step, shall fall within the scope of the present invention.
In the invention, the experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents, pharmaceutical excipients and other materials, if not otherwise specified, are all commercially available.
Example 1
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 10g of dogwood extract, 5g of lysimachia extract, 10g of scandent schefflera root extract, 10g of glabrous sarcandra herb volatile oil extract, 10g of lithospermum extract, 30g of rhizoma imperatae, 50g of madder extract, 20g of corydalis decumbens alkaloid extract, 10g of persimmon leaf extract, 10g of Jiangnan Chinese arborvitae biflavone extract, 10g of hairyvein agrimony flavone extract and 6g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition comprises the following steps:
s1, preparing fructus Corni extract, Lysimachia christinae extract, herba Gynostemmatis extract, herba Pileae Scriptae volatile oil extract, radix Arnebiae extract, radix Rubiae extract, rhizoma corydalis Decumbentis alkaloid extract, folium kaki extract, folium Platycladi flavone extract, herba et Gemma Agrimoniae flavone extract, and herba Leonuri alkaloid extract
S1.1, preparing the dogwood extract: pulverizing Corni fructus, adding 10 times of ethanol, performing Soxhlet reflux extraction for 2 times at 70 deg.C in water bath for 2 hr each time, mixing extractive solutions, and distilling under reduced pressure;
s1.2, preparation of lysimachia extract: crushing lysimachia, adding ethyl acetate/ethanol mixed solution with the volume ratio of 1:1 which is 3 times the weight of the raw materials, leaching for 3 times under the conditions of normal temperature and normal pressure, wherein the extraction time is 24 hours each time, combining the extracting solutions, decoloring by using powdery active carbon with the weight of 3 percent of the raw materials, filtering, and distilling under reduced pressure to obtain the lysimachia;
s1.3, the preparation method of the fiveleaf gynostemma herb extract is the same as that of the dogwood fruit extract in the S1.1, and the difference is that the extracting solution is concentrated under reduced pressure, passes through a macroporous resin column, is eluted by water, 60% ethanol, 75% ethanol and 90% ethanol in sequence, and is obtained after collecting eluent and carrying out reduced pressure distillation;
s1.4, preparing the glabrous sarcandra herb volatile oil extract: pulverizing herba Pileae Scriptae, adding 5 times of deionized water, wetting for 10min, heating at 90 deg.C, distilling, collecting distillate, and slowly adding into solution of inclusion agent;
s1.5, the preparation method of the lithospermum extract is the same as that of the dogwood extract in the S1.1, and the difference is that the extract is obtained by freezing and crystallizing after being decompressed and concentrated;
s1.6, preparing the madder root extract: pulverizing radix Rubiae, adding 25% ethanol 3 times the weight of the raw materials, extracting at 80 deg.C for 2 hr, decolorizing the extractive solution with powdered activated carbon 3% the weight of the raw materials, filtering, and distilling under reduced pressure to obtain extract;
s1.7, preparation of corydalis amabilis alkaloid extract: pulverizing rhizoma corydalis Decumbentis, adding 10 times of ethanol, extracting at 80 deg.C for 2 hr, concentrating the extractive solution to remove ethanol, adding 5% hydrochloric acid to adjust pH to 2, standing for 10 hr, filtering, adding 15% sodium hydroxide to adjust pH to 12, and filtering.
S1.8, the preparation method of the persimmon leaf extract is the same as that of the dogwood extract in the S1.1;
s1.9, the preparation method of the hinokitiol extract is the same as that of the dogwood extract in the S1.1, and the difference is that the extracting solution is obtained by extracting with petroleum ether and water and distilling the extracting solution under reduced pressure;
s1.10, the preparation method of the agrimony flavone extract is the same as that of the dogwood extract in the S1.1, but the difference is that the extract passes through a silica gel column, is eluted by ethyl acetate/petroleum ether 1:1, 3:1 and 5:1, and the eluent is obtained by reduced pressure distillation after passing through the gel column;
s1.11, the preparation method of the leonurus alkaloid extract is the same as that of the corydalis amabilis alkaloid extract in S1.7;
s2, weighing 10g of dogwood extract, 5g of lysimachia extract, 10g of scandent schefflera root extract, 10g of glabrous sarcandra herb volatile oil extract, 10g of lithospermum extract, 50g of madder extract, 20g of corydalis amabilis alkaloid extract, 10g of persimmon leaf extract, 10g of Jiangnan Chinese arborvitae biflavone extract, 10g of agrimony flavone extract and 6g of leonurus alkaloid extract which are prepared in the step S1; respectively crushing to 80 meshes, and then mixing and stirring uniformly to obtain a mixture A;
s3, weighing 30g of rhizoma imperatae, adding water in an amount which is 3 times the weight of the raw materials, decocting for 3 times at 90 ℃, wherein the decocting time is 30min each time, combining the decoction, filtering, concentrating the filtrate into paste, drying and crushing to obtain an extract B;
s4, mixing the mixture A obtained in the step S2 and the extract B obtained in the step S3, and uniformly stirring to obtain the Chinese herbal medicine composition;
s5, sieving the Chinese herbal medicine composition obtained in the step S4 by a 80-mesh sieve, adding pregelatinized starch accounting for 10% of the total weight of the medicine and magnesium stearate accounting for 0.5%, uniformly mixing, granulating, drying, and encapsulating to obtain the capsule.
Example 2
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 8g of dogwood extract, 5g of lysimachia sikokiana extract, 8g of scandent schefflera root extract, 8g of glabrous sarcandra herb volatile oil extract, 8g of lithospermum extract, 25g of rhizoma imperatae, 50g of madder extract, 23g of corydalis amabilis alkaloid extract, 8g of persimmon leaf extract, 6g of hinokiflavone extract, 6g of hairyvein agrimony flavone extract and 5g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of the embodiment 1, and the difference is that,
s5, sieving the Chinese herbal medicine composition obtained in S4 with a 100-mesh sieve, adding 15% of compressible starch, 15% of water, 2% of sodium carboxymethyl starch, 0.05% of sucrose and 0.03% of stevioside based on the total weight of the medicine, uniformly mixing, and preparing soft materials, granulating, drying, granulating and tabletting to obtain the tablet.
Example 3
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: the traditional Chinese medicine composition comprises 9g of dogwood extract, 2g of lysimachia extract, 11g of scandent schefflera root extract, 12g of glabrous sarcandra herb volatile oil extract, 12g of lithospermum extract, 35g of cogongrass rhizome, 54g of madder extract, 15g of corydalis amabilis alkaloid extract, 2g of persimmon leaf extract, 2g of Jiangnan Chinese arborvitae flavone extract, 2g of hairyvein agrimony flavone extract and 2g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of the embodiment 1, and the difference is that,
s5, sieving the Chinese herbal medicine composition obtained in S4 with a 80-mesh sieve, adding 15% of starch slurry, 10% of water, 3% of cross-linked polyvinylpyrrolidone, 0.05% of sucrose and 0.03% of stevioside, mixing uniformly, and preparing soft materials, preparing particles, drying and finishing particles to obtain the granules.
Example 4
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 12g of dogwood extract, 8g of lysimachia sikokiana extract, 12g of scandent schefflera root extract, 12g of glabrous sarcandra herb volatile oil extract, 12g of lithospermum extract, 40g of rhizoma imperatae, 55g of madder extract, 25g of corydalis amabilis alkaloid extract, 8g of persimmon leaf extract, 8g of Jiangnan Chinese arborvitae twig flavone extract, 8g of hairyvein agrimony flavone extract and 7g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of the embodiment 1, and the difference is that,
s5, sieving the Chinese herbal medicine composition obtained in S4 with a 100-mesh sieve, adding pregelatinized starch accounting for 15% of the total weight of the medicine, sucrose accounting for 0.05% of the total weight of the medicine and stevioside accounting for 0.03% of the total weight of the medicine, uniformly mixing, and performing granulation, drying and dosage division to obtain the powder.
Example 5
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 7g of dogwood extract, 2g of lysimachia extract, 8g of scandent schefflera root extract, 30g of glabrous sarcandra herb volatile oil extract, 25g of lithospermum extract, 45g of rhizoma imperatae, 53g of madder extract, 20g of corydalis amabilis alkaloid extract, 20g of persimmon leaf extract, 20g of Jiangnan Chinese arborvitae biflavone extract, 10g of hairyvein agrimony flavone extract and 15g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of example 1.
Example 6
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 15g of dogwood extract, 10g of lysimachia extract, 15g of scandent schefflera root extract, 8g of glabrous sarcandra herb volatile oil extract, 8g of lithospermum extract, 25g of cogongrass rhizome, 45g of madder extract, 13g of corydalis amabilis alkaloid extract, 2g of persimmon leaf extract, 2g of Jiangnan Chinese arborvitae biflavone extract, 2g of hairyvein agrimony flavone extract and 2g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of example 1.
Example 7
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 18g of dogwood extract, 13g of lysimachia sikokiana extract, 17g of scandent schefflera root extract, 35g of glabrous sarcandra herb volatile oil extract, 30g of lithospermum extract, 30g of rhizoma imperatae, 60g of madder extract, 50g of corydalis decumbens alkaloid extract, 25g of persimmon leaf extract, 23g of hinokiflavone extract, 13g of hairyvein agrimonia herb flavone extract and 20g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of example 1.
Example 8
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 6g of dogwood extract, 2g of lysimachia extract, 8g of scandent schefflera root extract, 8g of glabrous sarcandra herb volatile oil extract, 8g of lithospermum extract, 20g of rhizoma imperatae, 40g of madder extract, 12g of corydalis amabilis alkaloid extract, 2g of persimmon leaf extract, 2g of Jiangnan Chinese arborvitae flavone extract, 2g of hairyvein agrimony flavone extract and 2g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of example 1.
Example 9
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 20g of dogwood extract, 15g of lysimachia sikokiana extract, 20g of scandent schefflera root extract, 40g of glabrous sarcandra herb volatile oil extract, 35g of lithospermum extract, 60g of rhizoma imperatae, 70g of madder extract, 55g of corydalis decumbens alkaloid extract, 30g of persimmon leaf extract, 27g of hinokiflavone extract, 15g of hairyvein agrimonia herb flavone extract and 25g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of example 1.
Example 10
The embodiment of the invention provides a Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura, which comprises the following components in part by weight: 4g of dogwood extract, 2g of lysimachia sikokiana extract, 8g of scandent schefflera root extract, 8g of glabrous sarcandra herb volatile oil extract, 8g of lithospermum extract, 12g of rhizoma imperatae, 35g of madder extract, 10g of corydalis amabilis alkaloid extract, 2g of persimmon leaf extract, 2g of Jiangnan Chinese arborvitae twig flavone extract, 2g of hairyvein agrimony flavone extract and 2g of leonurus alkaloid extract.
The preparation method of the Chinese herbal medicine composition is the same as that of example 1.
The Chinese herbal medicine compositions for preventing and treating thrombocytopenic purpura provided in embodiments 1-10 of the present invention all have the obvious effect of increasing the number of platelets in peripheral blood, so that it is within the scope of the present invention to combine the composition or its active ingredients with pharmaceutical excipients to make an oral preparation, as long as the preparation is used for preventing and treating thrombocytopenic purpura.
Pharmacodynamic test
1. Experimental materials: 15 healthy male mice were taken, and the weights were 18 + -2 g, and were purchased from the center of laboratory animals in Guangdong province.
2. Experimental drugs: the Chinese herbal medicine composition prepared in example 1 was dissolved in water to prepare a liquid medicine A containing 0.2% of the drug.
Pulverizing herba Selaginellae Involventis, dissolving in water, and making into medicinal liquid B with medicinal content of 0.2%.
3. Establishing a model: 10 mice are taken and are respectively injected with (platelet antiserum) APS in the abdominal cavity for 7 days continuously, once a day and 0.1ml each time, so that chronic continuous thrombocytopenia of the mice is caused, and the model establishment is successful.
4. Grouping administration:
normal group: normal mice 5 were each drenched with 0.2ml of physiological saline;
model group: the 5 model mice are respectively infused with 0.2ml of liquid medicine B;
administration group: the 5 model mice are respectively infused with 0.2ml of liquid medicine A;
the administration was performed once a day for 7 days, and then blood was collected intravenously to examine the change of platelets in peripheral veins of mice before and after the administration.
5. Test results
The comparison of the number of platelets in peripheral veins of mice before and 7 days after administration is shown in Table 1.
Table 1 comparison of platelet counts
As can be seen from the results in Table 1, the number of platelets in the peripheral blood of the normal mice does not change much before and after administration, but the number of platelets in the peripheral blood of the mice in the administration group is obviously increased after the administration of the drug solution of the invention in the embodiment 1 and is closer to the number of platelets in the model group before and after administration, which indicates that the Chinese herbal medicine composition of the invention has the obvious effect of increasing the number of platelets in the peripheral blood and can be used for replacing the existing drugs for treating thrombocytopenic purpura.
Clinical medical records:
case 1
Zhang Yi, woman, 20 years old, student, through hospital hospitalization, confirmed primary thrombocytopenic purpura, through various methods of treatment are ineffective, the number of platelets is reduced to 20.00 + -0.45 × 109L, side effects of the hormone are evident. After 6 and 15 days in 2012, the composition capsule of the invention in example 1 is used for treating the platelet, 3 particles are taken each time, three times a day are taken regularly, the platelet is basically cured in 10 months in 2013, and the platelet is checked regularly to be normal, and the platelet is still maintained at 65.78 +/-0.75 multiplied by 10 currently9More than/L.
Case 2
Liao, female, 45 years old, diagnosed by hospital as idiopathic thrombocytopenic purpura, leukopenia, psoriasis, and ineffective hospitalization, and the number of platelets is reduced to 10.15 + -0.45 × 109The following,/L, symptoms: pale complexionWhite tongue coating, thin and white tongue coating, thready, rapid and slightly wiry pulse and the like, 6 flaky bleeding areas (right 2 and left 4) are formed in the two lower limbs, and the treatment is carried out by the composition capsule of the embodiment 1 of the invention (western medicines such as stopping hormone and the like) in 2013, 8 and 29 days. 4 granules at each time, three times daily, periodically checking platelets until the platelet is raised to 20.14 +/-0.45X 10 by 9 months and 25 days in 20139And L. Slightly improved air color, and consistent treatment, the blood platelet is raised to 57.41 +/-0.75 multiplied by 10 after 12 months and 20 days in 20149And L. (Normal 50X 10)9from/L to 100X 109L). In the treatment process, the existing method has good complexion, free life and no discomfort, and can normally participate in labor.
Case 3
Lu Yi (Lu Yi in China), male, or 35 years old, the number of platelets is reduced to 9.68 +/-0.45X 10 due to the ineffective rescue treatment of hospitalization for acute idiopathic thrombocytopenic purpura9L, life is critically ill, the whole body bleeding spot tablet accounts for more than 50 percent of the surface area of the body, and after the composition tablet of the embodiment 2 of the invention is taken, the blood platelets are raised to 64.45 +/-0.75 multiplied by 10 after the treatment year9L, follow-up all normal.
Case 4
Old men, 16 years old and 4 months 2012 have no effect on two acute hospitalizations due to acute thrombocytopenic purpura, and the platelets are reduced by about 3 thousand per day on average. After two treatment courses (14 months) of the composition tablet of example 2 of the present invention, platelets recovered to normal. The number of blood platelets checked two years later is a normal value (normal 50X 10)9from/L to 100X 109L), all normal after follow-up.
The present invention is not limited to the above preferred embodiments, and any modifications, equivalent substitutions and improvements made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (8)
1. A Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura is characterized by being prepared from the following raw materials in parts by weight: 4-20 parts of dogwood extract, 2-15 parts of lysimachia, 8-20 parts of scandent schefflera root extract, 8-40 parts of glabrous sarcandra herb volatile oil extract, 8-35 parts of lithospermum extract, 12-60 parts of cogongrass rhizome, 35-70 parts of madder extract, 10-55 parts of corydalis decumbens alkaloid extract, 2-30 parts of persimmon leaf extract, 2-27 parts of hinokiflavone extract, 2-15 parts of hairyvein agrimony flavone extract and 2-25 parts of leonurus alkaloid extract;
the dogwood extract, the lithospermum extract, the persimmon leaf extract, the Jiangnan Chinese arborvitae twig and leaf extract, the hairyvein agrimony flavone extract and the fiveleaf gynostemma herb extract are obtained by performing Soxhlet reflux extraction on ethanol and then concentrating; the lysimachia extract is obtained by adopting ethyl acetate/ethanol mixed liquor with the volume ratio of 1:1 for extraction; the madder root extract is obtained by ethanol extraction; the glabrous sarcandra herb volatile oil extract is obtained by extracting in water through steam distillation; the corydalis amabilis alkaloid extract and the leonurus alkaloid extract are obtained by adopting ethanol heat extraction and then acid-alkali precipitation.
2. The Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura according to claim 1, which is prepared from the following raw materials in parts by weight: 8-12 parts of dogwood extract, 2-8 parts of lysimachia, 8-12 parts of scandent schefflera root extract, 8-12 parts of glabrous sarcandra herb volatile oil extract, 8-12 parts of lithospermum extract, 25-40 parts of cogongrass rhizome, 50-55 parts of madder extract, 15-25 parts of corydalis decumbens alkaloid extract, 2-8 parts of persimmon leaf extract, 2-8 parts of Jiangnan Chinese arborvitae flavone extract, 2-8 parts of hairyvein agrimony flavone extract and 2-7 parts of leonurus alkaloid extract.
3. The Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura according to claim 2, which is prepared from the following raw materials in parts by weight: 10 parts of dogwood extract, 5 parts of lysimachia extract, 10 parts of scandent schefflera root extract, 10 parts of glabrous sarcandra herb volatile oil extract, 10 parts of lithospermum extract, 30 parts of cogongrass rhizome, 50 parts of madder extract, 20 parts of corydalis amabilis alkaloid extract, 10 parts of persimmon leaf extract, 10 parts of Jiangnan Chinese arborvitae twig flavone extract, 10 parts of hairyvein agrimony flavone extract and 6 parts of leonurus alkaloid extract.
4. The herbal composition for preventing and treating thrombocytopenic purpura according to any one of claims 1-3, wherein the cornus officinalis extract, lithospermum erythrorhizon extract, persimmon leaf extract, hinokitiol extract, agrimonia pilosa flavone extract and scandent schefflera leaf extract are obtained by pulverizing raw materials, adding ethanol in an amount 10 times the weight of the raw materials, performing Soxhlet extraction at 70 ℃ for 2 hours, and distilling the extractive solution under reduced pressure to remove the solvent.
5. The herbal composition for the prevention and treatment of thrombocytopenic purpura according to any of claims 1-3, wherein the lysimachia extract is obtained by pulverizing the raw material, adding an ethyl acetate/ethanol mixture in a volume ratio of 1:1 which is 3 times the weight of the raw material, leaching at room temperature and pressure for 24 hours, decolorizing the extract with powdered activated carbon in an amount of 3% by weight of the raw material, filtering, and distilling under reduced pressure to remove the solvent.
6. The herbal composition for the prevention and treatment of thrombocytopenic purpura according to any one of claims 1 to 3, wherein the extract of madder is obtained by pulverizing raw materials, adding 25 vol.% ethanol in an amount 3 times the weight of the raw materials, leaching at 80 ℃ for 2 hours, decolorizing the extract with powdered activated carbon in an amount 3% by weight of the raw materials, filtering, and distilling under reduced pressure to remove the solvent.
7. The herbal composition for the prevention and treatment of thrombocytopenic purpura according to any one of claims 1 to 3, wherein the said volatile oil extract of glabrous sarcandra herb is obtained by pulverizing raw materials, adding deionized water in an amount of 5 times the weight of the raw materials, wetting for 10min, distilling at 90 ℃ under heating, collecting the distillate, and adding the distillate to the solution of clathrating agent.
8. The herbal composition for treating and preventing thrombocytopenic purpura according to any one of claims 1-3, wherein said rhizoma corydalis Decumbentis alkaloid extract and said herba Leonuri alkaloid extract are prepared by pulverizing raw materials, adding 10 times of ethanol, heating and extracting at 80 deg.C for 2 hr, concentrating the extractive solution to remove ethanol, adding 5% hydrochloric acid to adjust pH to 2, standing for 10 hr, filtering, adding 15% sodium hydroxide to adjust pH to 12, and filtering.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910925553.0A CN110638946A (en) | 2019-09-27 | 2019-09-27 | Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910925553.0A CN110638946A (en) | 2019-09-27 | 2019-09-27 | Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110638946A true CN110638946A (en) | 2020-01-03 |
Family
ID=69011683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910925553.0A Pending CN110638946A (en) | 2019-09-27 | 2019-09-27 | Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110638946A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1839953A (en) * | 2005-03-31 | 2006-10-04 | 张涌川 | Medicine for treating idiopathy thrombocytopenia peliosis |
| CN102727746A (en) * | 2012-05-31 | 2012-10-17 | 固镇县中医院 | Chinese herbal decoction for treating qi-blood deficiency type thrombocytopenia |
| CN102727709A (en) * | 2012-05-31 | 2012-10-17 | 固镇县中医院 | Chinese herbal pill for treating spleen deficiency type thrombocytopenia |
| CN102727664A (en) * | 2012-05-31 | 2012-10-17 | 固镇县中医院 | Chinese herbal preparation for treating thrombocytopenia |
| CN104147419A (en) * | 2014-08-25 | 2014-11-19 | 庄立 | Traditional Chinese medicine composition for treating immune thrombocytopenia |
-
2019
- 2019-09-27 CN CN201910925553.0A patent/CN110638946A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1839953A (en) * | 2005-03-31 | 2006-10-04 | 张涌川 | Medicine for treating idiopathy thrombocytopenia peliosis |
| CN102727746A (en) * | 2012-05-31 | 2012-10-17 | 固镇县中医院 | Chinese herbal decoction for treating qi-blood deficiency type thrombocytopenia |
| CN102727709A (en) * | 2012-05-31 | 2012-10-17 | 固镇县中医院 | Chinese herbal pill for treating spleen deficiency type thrombocytopenia |
| CN102727664A (en) * | 2012-05-31 | 2012-10-17 | 固镇县中医院 | Chinese herbal preparation for treating thrombocytopenia |
| CN104147419A (en) * | 2014-08-25 | 2014-11-19 | 庄立 | Traditional Chinese medicine composition for treating immune thrombocytopenia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN103341145B (en) | Traditional Chinese medicine for treating psoriasis and preparation method thereof | |
| CN102940779A (en) | Medicine composition for treating chronic ulcerative colitis and preparation process of medicine composition | |
| US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
| CN103446525A (en) | Traditional Chinese medicine composition for treating skin diseases as well as preparation method and application of traditional Chinese medicine composition | |
| CN108619355A (en) | A kind of antitumor Chinese and preparation method thereof | |
| CN102357195A (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN104173950A (en) | Chinese herbal medicine composition for treating prostatic cancer | |
| CN103610795B (en) | A kind of preparation method of eucommia bark depressor oral formulations | |
| CN102038799B (en) | Application of breast lump-elimination preparation in preparing medicines for treating dysmenorrhea | |
| CN104324149A (en) | Medicament for dysmenorrhea and preparation method thereof | |
| CN101554471B (en) | Traditional Chinese medicine preparation for treating myocardial infarction | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN110638946A (en) | Chinese herbal medicine composition for preventing and treating thrombocytopenic purpura | |
| CN103356731B (en) | Pharmaceutical composition containing Cortex Eucommiae extract and Radix Notoginseng total arasaponins and application thereof | |
| CN102188580B (en) | Externally used traditional Chinese medicine composition and cataplasm for treating lobular hyperplasia of mammary gland, and preparation methods thereof | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN1279951C (en) | Pure Chinese traditional medicine capsule for treating hyperthyroidism and simple goiter | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN106963919B (en) | Chinese patent medicine for stopping bleeding and easing pain and preparation method and application thereof | |
| CN115400175B (en) | Traditional Chinese medicine composition for treating chronic renal failure | |
| CN103301380A (en) | Liver-soothing and qi-regulating traditional Chinese medicinal composition and preparation method thereof | |
| CN102451330A (en) | Traditional Chinese medicine for treating sterility due to blood stasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200103 |
|
| RJ01 | Rejection of invention patent application after publication |